ALNY Valuation

Alnylam Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

339.800

+9.25(2.798%)1D

Overview
Forecast
Valuation
Earnings

ALNY Relative Valuation

ALNY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALNY is overvalued; if below, it's undervalued.

Historical Valuation

Alnylam Pharmaceuticals Inc (ALNY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 12.75 is considered Undervalued compared with the five-year average of -62.34. The fair price of Alnylam Pharmaceuticals Inc (ALNY) is between 332.98 to 518.53 according to relative valuation methord. Compared to the current price of 330.55 USD , Alnylam Pharmaceuticals Inc is Undervalued By 0.73%.

Relative Value

Fair Zone

332.98-518.53

Current Price：330.55

0.73%

Undervalued

-940.57

Trailing

Forward

138.44

EV/EBITDA

Alnylam Pharmaceuticals Inc. (ALNY) has a current EV/EBITDA of 138.44. The 5-year average EV/EBITDA is -7425.74. The thresholds are as follows: Strongly Undervalued below -124400.50, Undervalued between -124400.50 and -65913.12, Fairly Valued between 51061.64 and -65913.12, Overvalued between 51061.64 and 109549.02, and Strongly Overvalued above 109549.02. The current Forward EV/EBITDA of 138.44 falls within the Historic Trend Line -Fairly Valued range.

846.25

EV/EBIT

Alnylam Pharmaceuticals Inc. (ALNY) has a current EV/EBIT of 846.25. The 5-year average EV/EBIT is -71.59. The thresholds are as follows: Strongly Undervalued below -1589.36, Undervalued between -1589.36 and -830.48, Fairly Valued between 687.29 and -830.48, Overvalued between 687.29 and 1446.18, and Strongly Overvalued above 1446.18. The current Forward EV/EBIT of 846.25 falls within the Overvalued range.

12.87

Alnylam Pharmaceuticals Inc. (ALNY) has a current PS of 12.87. The 5-year average PS is 16.45. The thresholds are as follows: Strongly Undervalued below 7.53, Undervalued between 7.53 and 11.99, Fairly Valued between 20.91 and 11.99, Overvalued between 20.91 and 25.37, and Strongly Overvalued above 25.37. The current Forward PS of 12.87 falls within the Historic Trend Line -Fairly Valued range.

222.60

P/OCF

Alnylam Pharmaceuticals Inc. (ALNY) has a current P/OCF of 222.60. The 5-year average P/OCF is 98.71. The thresholds are as follows: Strongly Undervalued below -594.94, Undervalued between -594.94 and -248.11, Fairly Valued between 445.54 and -248.11, Overvalued between 445.54 and 792.36, and Strongly Overvalued above 792.36. The current Forward P/OCF of 222.60 falls within the Historic Trend Line -Fairly Valued range.

109.72

P/FCF

Alnylam Pharmaceuticals Inc. (ALNY) has a current P/FCF of 109.72. The 5-year average P/FCF is -77.43. The thresholds are as follows: Strongly Undervalued below -1777.62, Undervalued between -1777.62 and -927.53, Fairly Valued between 772.67 and -927.53, Overvalued between 772.67 and 1622.77, and Strongly Overvalued above 1622.77. The current Forward P/FCF of 109.72 falls within the Historic Trend Line -Fairly Valued range.

Alnylam Pharmaceuticals Inc (ALNY) has a current Price-to-Book (P/B) ratio of 371.86. Compared to its 3-year average P/B ratio of -1124.96 , the current P/B ratio is approximately -133.06% higher. Relative to its 5-year average P/B ratio of -659.64, the current P/B ratio is about -156.37% higher. Alnylam Pharmaceuticals Inc (ALNY) has a Forward Free Cash Flow (FCF) yield of approximately -0.18%. Compared to its 3-year average FCF yield of -0.83%, the current FCF yield is approximately -78.50% lower. Relative to its 5-year average FCF yield of -2.10% , the current FCF yield is about -91.51% lower.

388.40

P/B

Median3y

-1124.96

Median5y

-659.64

-0.17

FCF Yield

Median3y

-0.83

Median5y

-2.10

Competitors Valuation Multiple

The average P/S ratio for ALNY's competitors is 14.14, providing a benchmark for relative valuation. Alnylam Pharmaceuticals Inc Corp (ALNY) exhibits a P/S ratio of 12.75, which is -9.83% above the industry average. Given its robust revenue growth of 20.20%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ALNY.O

Alnylam Pharmaceuticals Inc

Ascentage Pharma Group International

48.92

14.90B

REGN.O

Regeneron Pharmaceuticals Inc

Performance Decomposition

Market capitalization of ALNY increased by 39.20% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -111.92 to -163.97.

The secondary factor is the Revenue Growth, contributed 20.20%to the performance.

Overall, the performance of ALNY in the past 1 year is driven by P/E Change. Which is more unsustainable.

20.20%

494.33M → 594.19M

Revenue Growth

-27.51%

-13.34 → -9.67

Margin Expansion

46.51%

-111.92 → -163.97

P/E Change

39.20%